Juan Navarro-Barriuso

Juan Navarro-Barriuso

Auto-generated profile, based on publicly available information

Juan Navarro-Barriuso

Division of Immunology, Germans Trias i Pujol University Hospital and Research Institute, Campus Can Ruti, Badalona, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2014 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
MMMaria Jose Mansilla
Maria Jose Mansilla
CSCarla Sellès‐Moreno
Carla Sellès‐Moreno
SFSara Fàbregas‐Puig
Sara Fàbregas‐Puig
JAJoan Amoedo
Joan Amoedo
JNJuan Navarro‐Barriuso
Juan Navarro‐Barriuso
ECEva Mª Martínez Cáceres
Eva Mª Martínez Cáceres

8 June 2017 in Nanomedicine
Verified
Journal Article
Open access
IPIrma Pujol-Autonell
Irma Pujol-Autonell
MMMaria-Jose Mansilla
Maria-Jose Mansilla
SRSilvia Rodriguez-Fernandez
Silvia Rodriguez-Fernandez
MCMary Cano
Mary Cano
JNJuan Navarro-Barriuso
Juan Navarro-Barriuso
MVMarta Vives-Pi
Marta Vives-Pi
Aim: Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. Materials & methods: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo. Results: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. Conclusion: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.

8 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JNJuan Navarro-Barriuso
Juan Navarro-Barriuso
MMMaría José Mansilla
María José Mansilla
MNMar Naranjo-Gomez
Mar Naranjo-Gomez
ASAlex Sánchez-Pla
Alex Sánchez-Pla
BQBibiana Quirant-Sánchez
Bibiana Quirant-Sánchez
ECEva Mª Martínez Cáceres
Eva Mª Martínez Cáceres
Tolerogenic dendritic cell (tolDC)-based therapies have become a promising approach for the treatment of autoimmune diseases by their potential ability to restore immune tolerance in an antigen-specific manner. However, the broad variety of protocols used to generate tolDCin vitroand their functional and phenotypical heterogeneity are evidencing the need to find robust biomarkers as a key point towards their translation into the clinic, as well as better understanding the mechanisms involved in the induction of immune tolerance. With that aim, in this study we have compared the transcriptomic profile of tolDC induced with either vitamin D3 (vitD3-tolDC), dexamethasone (dexa-tolDC) or rapamycin (rapa-tolDC) through a microarray analysis in 5 healthy donors. The results evidenced that common differentially expressed genes could not be found for the three different tolDC protocols. However, individually,CYP24A1,MUCL1andMAP7for vitD3-tolDC;CD163,CCL18,C1QBandC1QCfor dexa-tolDC; andCNGA1andCYP7B1for rapa-tolDC, constituted good candidate biomarkers for each respective cellular product. In addition, a further gene set enrichment analysis of the data revealed that dexa-tolDC and vitD3-tolDC share several immune regulatory and anti-inflammatory pathways, while rapa-tolDC seem to be playing a totally different role towards tolerance induction through a strong immunosuppression of their cellular processes.

20 May 2016 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MMMaria Jose Mansilla
Maria Jose Mansilla
RCRaian Contreras-Cardone
Raian Contreras-Cardone
JNJuan Navarro-Barriuso
Juan Navarro-Barriuso
NCNathalie Cools
Nathalie Cools
ZBZwi Berneman
Zwi Berneman
ECEva Mª Martínez Cáceres
Eva Mª Martínez Cáceres
Tolerogenic dendritic cells (tolDC) have been postulated as a potent immunoregulatory therapy for autoimmune diseases such as multiple sclerosis (MS). In a previous study, we demonstrated that the administration of antigen-specific vitamin D3 (vitD3) tolDC in mice showing clinical signs of experimental autoimmune encephalomyelitis (EAE; the animal model of MS) resulted in abrogation of disease progression. With the purpose to translate this beneficial therapy to the clinics, we have investigated the effectivity of vitD3-frozen antigen-specific tolDC pulsed with myelin oligodendrocyte glycoprotein 40-55 peptide (f-tolDC-MOG) since it would reduce the cost, functional variability and number of leukapheresis to perform to the patients. Mice showing EAE clinical signs were treated with repetitive doses of f-tolDC-MOG. Tolerogenic mechanisms induced by the therapy were analysed by flow cytometry and T cell proliferation assays. Treatment with f-tolDC-MOG was effective in ameliorating clinical signs of mice with EAE, inhibiting antigen-specific reactivity and inducing Treg. In addition, the long-term treatment was well tolerated and leading to a prolonged maintenance of tolerogenicity mediated by induction of Breg, reduction of NK cells and activation of immunoregulatory NKT cells. The outcomes of this study show that the use of antigen-specific f-tolDC promotes multiple and potent tolerogenic mechanisms. Moreover, these cells can be kept frozen maintaining their tolerogenic properties, which is a relevant step for their translation to the clinic. Altogether, vitD3 f-tolDC-MOG is a potential strategy to arrest the autoimmune destruction in MS patients.

19 September 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
JNJuan Navarro-Barriuso
Juan Navarro-Barriuso
MMMaría José Mansilla
María José Mansilla
ECEva Mª Martínez Cáceres
Eva Mª Martínez Cáceres
The last years have witnessed a breakthrough in the development of cell-based tolerance-inducing cell therapies for the treatment of autoimmune diseases and solid-organ transplantation. Indeed, the use of tolerogenic dendritic cells (tolDC) and regulatory macrophages (Mreg) is currently being tested in Phase I and Phase II clinical trials worldwide, with the aim of finding an effective therapy able to abrogate the inflammatory processes causing these pathologies without compromising the protective immunity of the patients. However, there exists a wide variety of different protocols to generate human tolDC and Mreg and, consequently, the characteristics of each product are heterogeneous. For this reason, the identification of biomarkers able to define their functionality (tolerogenicity) is of great relevance, on the one hand, to guarantee the safety of tolDC and Mreg before administration and, on the other hand, to compare the results between different cell products and laboratories. In this article, we perform an exhaustive review of protocols generating human tolDC and Mreg in the literature, aiming to elucidate if there are any common transcriptomic signature or potential biomarkers of tolerogenicity among the different approaches. However, and although several effectors seem to be induced in common in some of the most reported protocols to generate both tolDC or Mreg, the transcriptomic profile of these cellular products strongly varies depending on the approach used to generate them.

15 April 2018 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
BQBibiana Quirant
Bibiana Quirant
JHJosé V. Hervás‐García
José V. Hervás‐García
ATAina Teniente-Serra
Aina Teniente-Serra
LBLluís Brieva
Lluís Brieva
EMEster Moral‐Torres
Ester Moral‐Torres
ECEva Mª Martínez Cáceres
Eva Mª Martínez Cáceres